Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Ph 2 Trial 17 Oct Written by Carla Aguilera Siebert N, Troschke-Meurer S, Marx M, Zumpe M, Ehlert K, Gray J, Garaventa A, Manzitti C, Ash S, Klingebiel T, Beck J, Castel V, Valteau-Couanet D, Loibner H, Ladenstein R, Lode HN.Cancers (Basel). 2018 Oct 17;10(10):387. doi: 10.3390/cancers10100387. PMID: 30336605; PMCID: PMC6210332. 2018 Carla Aguilera Previous Previous Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study Next Next I-131 mIBG Scintigraphy Curie Versus SIOPEN Scoring: Prognostic Value in Stage 4 Neuroblastoma
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Ph 2 Trial 17 Oct Written by Carla Aguilera Siebert N, Troschke-Meurer S, Marx M, Zumpe M, Ehlert K, Gray J, Garaventa A, Manzitti C, Ash S, Klingebiel T, Beck J, Castel V, Valteau-Couanet D, Loibner H, Ladenstein R, Lode HN.Cancers (Basel). 2018 Oct 17;10(10):387. doi: 10.3390/cancers10100387. PMID: 30336605; PMCID: PMC6210332. 2018 Carla Aguilera
